Receive our newsletter – data, insights and analysis delivered to you
  1. News
October 20, 2021

Johnson & Johnson reports 10.7% rise in Q3 2021 sales

The 2021 full-year guidance for operational sales were raised from $92.8bn to $93.3bn, which comprises sales of its Covid-19 shots.

Johnson & Johnson (J&J) has reported sales of $23.3bn in the third quarter (Q3) of 2021, a rise of 10.7% compared to $21.08bn in the same quarter last year.

For the quarter, the net earnings were recorded at $3.67bn, an increase of 3.2% against $3.55bn during last year’s quarter.

In the US, the reported sales of the company rose by 7.9% to $11.96bn in Q3 compared to $11.08bn last year.

During the same quarter, international and worldwide sales grew by 13.8% and 10.7%, respectively.

The pharmaceutical segment of J&J recorded a 13.8% increase in sales to $12.99bn in the third quarter of 2021 versus $11.42bn in the same quarter a year ago.

Furthermore, the pharmaceutical global operational sales increased 13.8%, which excluded the net effect of acquisitions and divestitures.

Content from our partners
How Hengst helped to keep Germany’s charity “star singers” shining
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

Drugs such as Darzalex, Stelara, Tremfya and the company’s Covid-19 vaccine drove the growth in sales.

J&J reported that a rise of 8% in sales from $6.64bn in Q3 2021 as against $6.15bn last year were recorded in the medical devices segment.

J&J increased its 2021 full-year guidance for operational sales from $92.8bn to $93.3bn including Covid-19 vaccine sales from $92.5bn to $93.3bn in July.

The diluted adjusted EPS was also raised to $9.77 to $9.82 from $9.60 to $9.70.

Johnson & Johnson chairman and CEO Alex Gorsky said: “Our third-quarter results demonstrate solid performance across Johnson & Johnson, driven by robust above-market results in Pharmaceuticals, ongoing recovery in Medical Devices, and strong growth in Consumer Health.

“In the face of evolving marketplace dynamics resulting from the effects of Covid-19 and other global trends, we have continued to demonstrate the responsiveness and agility required to meet the needs of our stakeholders while also successfully investing in a pipeline of innovation and key commercial platforms to drive our future growth.”

In July, J&J recorded sales of $23.31bn in the Q2 of 2021, an increase of 27.1% versus $18.33bn in Q2 last year.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy